> Details

Eggleston, Karen [Author] ; Chen, Brian [Other]; Chen, Chih-Hung [Other]; Chen, Ying Isabel [Other]; Feenstra, Talitha [Other]; Iizuka, Toshiaki [Other]; Lam, Janet Tinkei [Other]; Leung, Gabriel [Other]; Lu, Jui-fen [Other]; Rodriguez-Sanchez, Beatriz [Other]; Struijs, Jeroen [Other]; Quan, Jianchao [Other]; Newhouse, Joseph P. [Other]

Are Quality-Adjusted Medical Prices Declining for Chronic Disease? Evidence from Diabetes Care in Four Health Systems

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Book
  • Title: Are Quality-Adjusted Medical Prices Declining for Chronic Disease? Evidence from Diabetes Care in Four Health Systems
  • Contributor: Eggleston, Karen [Author]; Chen, Brian [Other]; Chen, Chih-Hung [Other]; Chen, Ying Isabel [Other]; Feenstra, Talitha [Other]; Iizuka, Toshiaki [Other]; Lam, Janet Tinkei [Other]; Leung, Gabriel [Other]; Lu, Jui-fen [Other]; Rodriguez-Sanchez, Beatriz [Other]; Struijs, Jeroen [Other]; Quan, Jianchao [Other]; Newhouse, Joseph P. [Other]
  • Published: [S.l.]: SSRN, [2019]
  • Published in: NBER Working Paper ; No. w25971
  • Extent: 1 Online-Ressource (38 p)
  • Language: English
  • Origination:
  • Footnote: Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments June 2019 erstellt
  • Description: Improvements in medical treatment have contributed to rising health spending. Yet there is relatively little evidence on whether the spending increase is “worth it” in the sense of producing better health outcomes of commensurate value—a critical question for understanding productivity in the health sector and, as that sector grows, for deriving an accurate quality-adjusted price index for an entire economy. We analyze individual-level panel data on medical spending and health outcomes for 123,548 patients with type 2 diabetes in four health systems. Using a “cost-of-living” method that measures value based on improved survival, we find a positive net value of diabetes care: the value of improved survival outweighs the added costs of care in each of the four health systems. This finding is robust to accounting for selective survival, end-of-life spending, and a range of values for a life-year or, equivalently, to attributing only a fraction of survival improvements to medical care.Institutional subscribers to the NBER working paper series, and residents of developing countries may download this paper without additional charge at "http://www.nber.org/papers/w25971"
  • Access State: Open Access